Lipid Nanoparticles As Delivery Systems for RNA-Based Vaccines

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2021 Feb 5

PMID 33540942

Citations 86

Authors

Basmah N Aldosari

Iman M Alfagih

Alanood S Almurshedi

Affiliations

Soon will be listed here.

Abstract

There has been increased interest in the development of RNA-based vaccines for protection against various infectious diseases and also for cancer immunotherapies. Rapid and cost-effective manufacturing methods in addition to potent immune responses observed in preclinical and clinical studies have made mRNA-based vaccines promising alternatives to conventional vaccine technologies. However, efficient delivery of these vaccines requires that the mRNA be protected against extracellular degradation. Lipid nanoparticles (LNPs) have been extensively studied as non-viral vectors for the delivery of mRNA to target cells because of their relatively easy and scalable manufacturing processes. This review highlights key advances in the development of LNPs and reviews the application of mRNA-based vaccines formulated in LNPs for use against infectious diseases and cancer.

Citing Articles

Exploring the Effects of Incorporating Different Bioactive Phospholipids into Messenger Ribonucleic Acid Lipid Nanoparticle (mRNA LNP) Formulations.

Chen S, Wang S, Liao S, Blakney A ACS Bio Med Chem Au. 2025; 5(1):154-165.

PMID: 39990935 PMC: 11843334. DOI: 10.1021/acsbiomedchemau.4c00085.

Lipid Nanoparticle (LNP) -A Vector Suitable for Evolving Therapies for Advanced Hepatocellular Carcinoma (HCC).

Zhang M, Guo R, Yuan Z, Wang H Glob Chall. 2025; 9(1):2400217.

PMID: 39802046 PMC: 11717671. DOI: 10.1002/gch2.202400217.

The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems.

Parvin N, Mandal T, Joo S Pharmaceutics. 2024; 16(11).

PMID: 39598489 PMC: 11597542. DOI: 10.3390/pharmaceutics16111366.

Nanogene editing drug delivery systems in the treatment of liver fibrosis.

Wang Q, Jia S, Wang Z, Chen H, Jiang X, Li Y Front Med (Lausanne). 2024; 11:1418786.

PMID: 39386741 PMC: 11461213. DOI: 10.3389/fmed.2024.1418786.

Machine Learning Elucidates Design Features of Plasmid Deoxyribonucleic Acid Lipid Nanoparticles for Cell Type-Preferential Transfection.

Cheng L, Zhu Y, Ma J, Aggarwal A, Toh W, Shin C ACS Nano. 2024; 18(42):28735-28747.

PMID: 39375194 PMC: 11512640. DOI: 10.1021/acsnano.4c07615.

References

Semple S, Harasym T, Clow K, Ansell S, Klimuk S, Hope M . Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther. 2004; 312(3):1020-6. DOI: 10.1124/jpet.104.078113. View

Wadhwa A, Aljabbari A, Lokras A, Foged C, Thakur A . Opportunities and Challenges in the Delivery of mRNA-based Vaccines. Pharmaceutics. 2020; 12(2). PMC: 7076378. DOI: 10.3390/pharmaceutics12020102. View

Sahin U, Oehm P, Derhovanessian E, Jabulowsky R, Vormehr M, Gold M . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823):107-112. DOI: 10.1038/s41586-020-2537-9. View

Melief C, van Hall T, Arens R, Ossendorp F, van der Burg S . Therapeutic cancer vaccines. J Clin Invest. 2015; 125(9):3401-12. PMC: 4588240. DOI: 10.1172/JCI80009. View

Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Narayanannair Jayaprakash K . Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010; 18(7):1357-64. PMC: 2911264. DOI: 10.1038/mt.2010.85. View

Lu J, Lu G, Tan S, Xia J, Xiong H, Yu X . A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 2020; 30(10):936-939. PMC: 7429369. DOI: 10.1038/s41422-020-00392-7. View

John S, Yuzhakov O, Woods A, Deterling J, Hassett K, Shaw C . Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018; 36(12):1689-1699. DOI: 10.1016/j.vaccine.2018.01.029. View

Judge A, McClintock K, Phelps J, MacLachlan I . Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther. 2005; 13(2):328-37. DOI: 10.1016/j.ymthe.2005.09.014. View

Maruggi G, Zhang C, Li J, Ulmer J, Yu D . mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol Ther. 2019; 27(4):757-772. PMC: 6453507. DOI: 10.1016/j.ymthe.2019.01.020. View

10.

Salvati A, Pitek A, Monopoli M, Prapainop K, Bombelli F, Hristov D . Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013; 8(2):137-43. DOI: 10.1038/nnano.2012.237. View

11.

Martin M, Rice K . Peptide-guided gene delivery. AAPS J. 2007; 9(1):E18-29. PMC: 2751301. DOI: 10.1208/aapsj0901003. View

12.

Geall A, Verma A, Otten G, Shaw C, Hekele A, Banerjee K . Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012; 109(36):14604-9. PMC: 3437863. DOI: 10.1073/pnas.1209367109. View

13.

Corbett K, Flynn B, Foulds K, Francica J, Boyoglu-Barnum S, Werner A . Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020; 383(16):1544-1555. PMC: 7449230. DOI: 10.1056/NEJMoa2024671. View

14.

Jeffs L, Palmer L, Ambegia E, Giesbrecht C, Ewanick S, MacLachlan I . A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res. 2005; 22(3):362-72. DOI: 10.1007/s11095-004-1873-z. View

15.

Davis M . The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm. 2009; 6(3):659-68. DOI: 10.1021/mp900015y. View

16.

Semple S, Klimuk S, Harasym T, Dos Santos N, Ansell S, Wong K . Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta. 2001; 1510(1-2):152-66. DOI: 10.1016/s0005-2736(00)00343-6. View

17.

Chahal J, Fang T, Woodham A, Khan O, Ling J, Anderson D . An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci Rep. 2017; 7(1):252. PMC: 5427874. DOI: 10.1038/s41598-017-00193-w. View

18.

Zhang H, De Smedt S, Remaut K . Fluorescence Correlation Spectroscopy to find the critical balance between extracellular association and intracellular dissociation of mRNA complexes. Acta Biomater. 2018; 75:358-370. DOI: 10.1016/j.actbio.2018.05.016. View

19.

Gomez-Aguado I, Rodriguez-Castejon J, Vicente-Pascual M, Rodriguez-Gascon A, Solinis M, Del Pozo-Rodriguez A . Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives. Nanomaterials (Basel). 2020; 10(2). PMC: 7075285. DOI: 10.3390/nano10020364. View

20.

Song L, Ahkong Q, Rong Q, Wang Z, Ansell S, Hope M . Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim Biophys Acta. 2001; 1558(1):1-13. DOI: 10.1016/s0005-2736(01)00399-6. View